LIVN vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LIVN presents a stark contrast between poor deterministic health and strong market momentum. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, and the technical trend is currently bearish. However, the company maintains strong gross margins (68.01%) and a low debt-to-equity ratio (0.36), while analysts remain bullish with a target price of $79.64. The valuation appears attractive on a PEG basis (0.72), but the negative net profit margin and ROE suggest operational inefficiencies or significant non-operating losses.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LIVN vs MRK: Head-to-Head Comparison
This page compares LivaNova PLC (LIVN) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.